Skip to main content
. 2021 Dec 12;11(12):2339. doi: 10.3390/diagnostics11122339

Table 3.

Studies on the accuracy of CSF neurogranin for AD diagnosis.

Study Population Assay AUC Sensitivity Specificity Optimal Cut-Off Value (pg/mL)
Xue et al. [36] 111 cognitively-normal controls, 193 MCI, 95 AD Electrochemiluminescence
technology using Ng7
0.71 NA NA NA
Fan et al. [37] 65 cognitively-normal controls, 65 AD Electrochemiluminescence
technology using Ng7
0.783 NA NA NA
Galasko et al. [38] 90 normal controls, 46 AD ELISA (EUROIMMUN, Lübeck, Germany) 0.504 0.200
(0.022–0.311)
0.854
(0.640–0.932)
167.78
Schipke et al. [39] 20 MDD, 20 AD In-house ELISA 0.696 NA NA NA
Mattsson et al. [40] 93 controls, 93 AD In-house ELISA 0.85 NA NA 254.7
Tarawneh et al. [41] 207 controls, 95 AD 2-site immunoassay uses an affinity-efficient trapping and purification technique for polyclonal antibodies 0.71 NA NA NA
Janelidze et al. [42] 74 AD In-house ELISA 0.761 NA NA NA

MCI, mild cognitive impairment; AD, Alzheimer’s disease; NA, not available; ELISA, enzyme-linked immunosorbent assay; MDD, major depressive disorder.